Presenting Companies
Alintegimod is a first-in-class, oral small molecule designed to improve the effectiveness of immune checkpoint inhibitors against treatment-resistant solid tumors without adding toxicity. Alintegimod uniquely activates integrins, cell adhesion molecules critical to generating an effective anti-tumor immune response, including T cell activation and tumor infiltration. Alintegimod is the first clinical-stage molecule to emerge from 7 Hills Pharma’s proprietary platform of novel integrin agonists.
• Therapeutic AI Architect with established clinical proof-of-concept (POC)
• Proprietor of technology platforms and assets across multiple regions
• Innovator in novel drug development focused on addressing high-value unmet clinical needs
Adjuvia Therapeutics is developing novel small molecule nanoparticles to address chronic and debilitating diseases that arise from mitochondrial and cellular dysfunction. Adjuvia’s lead compound, ATI-103, is currently in IND-enabling studies to treat rare inherited mitochondrial diseases with high unmet medical needs, including Leigh Syndrome and Friedreich's Ataxia.
AIxMed is a global leader in non-GYN computational cytology, pioneering AI-powered solutions for bladder cancer (urine cytology) and thyroid FNAC diagnostics. Our flagship platform, AIxURO, is currently being validated by several of the largest urology-focused reference labs in the U.S. and Europe, demonstrating significant improvements in diagnostic accuracy, efficiency, and turnaround time. By collaborating with leading cytology key opinion leaders and seamlessly integrating with top-tier WSI scanners and image management systems, AIxMed is setting the foundation for the future standard in computational pathology. Backed by strong clinical evidence and a robust IP portfolio, AIxMed is advancing the adoption of AI-enabled cytology in routine clinical practice worldwide.
Alphyn’s first drug is poised to dominate the largest dermatological disease in the world, atopic dermatitis or AD also known as eczema, supported by competitive-advantage in its Phase 2 clinical trial results with first opportunity for liquidity event in 15 to 18 months at a potential 20x return based on market comparable liquidity events in AD.
Applied Cognition is a platform therapeutics company pioneering drug development by targeting the brain’s glymphatic system. Enhancing glymphatic function represents a first-in-class therapeutic approach for treating neurodegenerative diseases. Leveraging its patented platform, which allows continuous, real-time monitoring of glymphatic activity in humans, the company has identified its first therapeutic target and lead drug candidate to promote glymphatic clearance of amyloid and tau proteins. Applied Cognition is currently advancing this lead program for early-stage Alzheimer’s disease and expanding its pipeline to develop treatments for additional neurological conditions using its platform.
Avanti Biosciences is a biotechnology company focused on advancing ABI-01, an innovative small molecule dual PIM1/DYRK1 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and NASH-related liver fibrosis. The program has received prestigious recognition from the National Heart, Lung, and Blood Institute (NHLBI), with Avanti's Catalyze grant application scored as one of the top proposals, providing federal validation of the novel dual mechanism approach. ABI-01 has demonstrated superior preclinical safety and efficacy, including robust anti-fibrotic effects and best-in-class improvements in lung function compared to current therapies. The program is clinical trial-ready, with IND-enabling studies complete and no drug-related toxicities observed. Backed by an experienced leadership team, a strong IP portfolio, federal scientific endorsement, and FDA Orphan Drug Designation for IPF, Avanti is positioned to deliver transformative therapies for fibrotic diseases.
Bifrost Biosystems is a life sciences tools company offering high-throughput single-cell optical pooled screening and analysis solutions that deliver insights into functional cell biology and drug discovery. Our groundbreaking platform integrates innovations in single-cell biology, chemistry, engineering, imaging, AI, and computation. Now scientists can explore the underlying causes of human disease, discover promising new therapies, and unravel the complexities of microbial and mammalian cell biology with unprecedented scale and depth.
Cache DNA is building the next generation of biomolecule preservation solutions for the life sciences. After spinning out of MIT and the Illumina Accelerator, their team has been working with several commercial laboratories to streamline & automate sample storage workflows at room temperature. The democratization of sequencing across the -Omics, growing interest in liquid biopsy assays, and AI-catalyzed data mining of tissue have led to exponential growth in specimen repositories, a multi-billion-dollar market across the life sciences. Based in San Carlos, CA, they are raising $4M to close key accounts and accelerate their products’ path to market.
Cenna Biosciences, Inc. is a privately-held, clinical-stage biopharmaceutical company based in La Jolla, CA, focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s Disease (AD). Since its inception, Cenna has been funded almost entirely by non-dilutive funding, including over $21 million in NIH and other grants, with the most recent award of $2.7 million in September 2024, and by contributions from the Founders. Cenna is advancing Nubytide, a first-in-class peptide drug for Alzheimer’s Disease (AD), which inhibits the production of Aβ by a novel mechanism and which may be useful for both prevention and treatment of AD. Nubytide is a small peptide which is expected to be safer than the current monoclonal (Mab) drugs as peptides do not cause ARIAs, a common and dangerous side effect of Mab therapies, is easier to administer by simple subcutaneous injection rather than intravenous infusion and will be more cost efficient. Cenna has completed a pre-IND meeting with the FDA and is preparing to file IND within the next couple of months. We expect to begin our first-in-humans Phase 1 clinical trials at the beginning of 2026 and are seeking $10M to fund the studies.
CIAN was founded from the research of Dr. Ramani Ramchandran out of the Medical College of Wisconsin. Our technology is based on proteins found inside a microtubule-based organelle called cilia that is present in most cells in the body. Upon turbulent blood flow, cilia are dismantled from blood vessels and dissociate, a process called “deciliation.” Proteins from inside the cilium are released into the blood and can act as biomarkers for diagnostic tests. Our first product is a point-of-care test to diagnose and determine "return-to-activity" from traumatic brain injuries (concussion). This test is intended for use by athletes in contact sports and military service members.
Circurna is a biotechnology company pioneering next-generation vaccines and therapeutics with its proprietary ciRNA™ circular RNA platform. Our ciRNA™ platform delivers enhanced thermo-stability, durable expression, and reduced immuno and reactogenicity compared to linear mRNA, enabling new treatments for cancer, infectious, autoimmune, and other diseases. Circurna’s ciRNA platform powers circular RNA vaccines and protein therapeutics including antibodies, non-antibody proteins, peptides, multi-payload constructs and immuno-therapeutics to target a wide range of diseases. Circurna is backed by non-dilutive funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Institutes of Health (NIH) and has already raised an initial $1 million seed investment.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death.
DIMERx is an NIH-backed, clinical-stage biopharmaceutical company developing first-in-class, non-addictive dimer therapeutics targeting two urgent U.S. health priorities: pain management and vascular injury. Our platform is designed to treat acute and chronic pain without addiction risk and to address pulmonary and vascular complications seen in sickle cell disease and from nerve agent exposure.Our proprietary NCE lead asset, DMX-101, is a peripherally acting buprenorphine dimer that delivers potent analgesia without CNS exposure — eliminating addiction risk, sedation, and cognitive impairment. DMX-101 is backed by a $15M NIH HEAL Initiative grant, a DoD/DVCIPM collaboration for military applications, and validated in 400+ subjects across Phase 1 & 2 studies, DMX-101 is positioned for late-stage development and strategic partnering.
Drusolv Therapeutics is developing a patent-protected, clinically distinct formulation of oral atorvastatin for early intervention in a blinding eye disease called age-related macular degeneration (AMD). This is a $13B per year, completely unmet need. The objective is to exit via acquisition in three years after a pending, IND-approved Phase 2 trial, and recent ophthalmic drug M&A transactions after Phase 2 support an exit valuation of $1B. We are currently syndicating a $20M Series A round that will carry us through acquisition.
DuoBio is a U.S.-based spin-off from Acepodia, dedicated to the development of bispecific dual-payload ADCs. Our next-generation ADC platform is designed to reduce on-target/off-tumor toxicity and overcome drug resistance, with the ultimate goal of widening the therapeutic window and delivering improved outcomes for patients.
Elastrin Therapeutics' first-in-class therapy is designed to restore flexibility to stiffened arteries by resolving calcification that afflicts 50% of all persons over aged 55. The breakthrough combines a humanized, patented targeting antibody with a customized liposome to time-release an FDA-approved drug at sites where calcification nucleates around degraded elastin. Treatment is enhanced with an FDA-approved device for local infusion. Our initial indication in a robust pipeline is Peripheral Artery Disease (PAD). Efficacy is proven in human ex vivo and large animal models.
Cells make exosomes. Esphera SynBio modifies cells such that they make modified exosomes. These modified exosomes can be designed to have targeting moieties on their surface and a variety of protein or RNA payloads in their lumen.
FluGen is a clinical stage vaccine company moving to revolutionize the respiratory infectious disease vaccine space. It's intranasal M2SR platform is a M2-deleted Single Replication construct that has shown unprecedented responses in subjects for influenza including longer durability, breadth of protection against mutated strains and protection from infection. Existing influenza vaccines, including mRNA can claim none of these attributes. M2SR has been studied in 700 subjects for influenza and extensive animal models for RSV. In addition to its fundraising efforts, the Company enjoys support from the DOD, NIAID, BARDA and the Japanese Government.
GenBio AI operates at the intersection of artificial intelligence and biology, developing multiscale foundation models to understand and predict biological processes across all scales of life. Through its AI-driven Digital Organism (AIDO), the company enables predictive disease modeling, drug discovery acceleration, and bioengineering innovation. Founded by leading AI and computational biology experts from top global institutions, GenBio AI integrates pan-modal biological data to drive real-world biomedical impact. With hubs in Palo Alto, Paris, and Abu Dhabi, the company fosters international collaboration to advance AI-driven biology.
Geneos Therapeutics is a privately held P2b biotherapeutic company developing best-in-industry personalized immunotherapies for cancer (PICs) based on a proprietary DNA platform. PICs broaden tumor infiltrating lymphocyte (TIL) clonal repertoire by inducing new T cells clones directed to up to 40 personal neoantigens. Results from the GT-30 Phase 1b/2a trial in 2L advanced HCC are published in Nature Medicine. It achieved all prespecified endpoints for safety, immunogenicity, and efficacy (ORR), including 30% ORR of which 8% were CRs.100% of GT-30 patients assessed demonstrated CD8+ TILs directed to vaccine neoantigens, with > 85% of the T cells having the optimal activated, effector, cytotoxic phenotype. No prior therapeutic vaccine has ever achieved this degree of mechanistic success and the achievement of this magnitude of CRs in 2L advanced, unresectable or metastatic HCC is superior to any other form of treatment. A ~$40M Series B is ongoing to conduct GT-31, an international Phase 2b trial of PICs in adjuvant HCC.
GreenMark empowers Regenerative Dentistry for the Modern World. Dental caries (decay) is the world’s most prevalent chronic disease. Over 95% of Americans suffer from caries over their lifetimes and 74% of the population suffers from dental sensitivity. Current toothpastes contain minerals that are inert and not bioavailable. GreenMark has developed CrystLCare™ Biorestorative mineral-loaded starch particles that contain, protect, target, and deliver bioavailable minerals precisely to sites where needed, where they form hydroxyapatite, the main component of tooth enamel and dentin. Clinical applications include more effective treatment of dental sensitivity, and a no-drill treatment of early tooth decay with products that are much more effective than fluoride.
ImTol, Inc. is developing a next generation therapeutic platform to create low-cost, off-the-shelf, allogeneic therapies that activate the immune system and induce lasting immune tolerance for treating multiple sclerosis (MS), type 1 diabetes and other autoimmune diseases. Its lead therapy for MS induces immune tolerance against all myelin antigens, thus disrupting a key step in the pathogenesis of the disease and has the potential to stop disease progression in all forms of MS, including primary progressive MS. This approach solves current MS drugs’ biggest challenge – systemic immunosuppression and lack of specificity to MS – by selectively depleting disease-causing immune cells only, leaving the rest of immune system intact.
JangoPet has developed a novel stem cell therapy called Jango-Renew that dramatically improves pain and mobility in dogs with osteoarthritis. FDA approval of Jango-Renew would 1) provide veterinarians nationwide access to an off-the-shelf regenerative stem cell therapy for the treatment of osteoarthritis in dogs, and 2) allow commercialization of this first-in-class biologic to a market of 20 million afflicted dogs worth billions of dollars annually.
KeifeRx is a biopharma company building upon its extensive clinical experience in neurodegenerative diseases to advance kinase Inhibitors that attack neurodegenerative diseases at their root cause. Our drug candidates restore autophagy and attack the three pillars of neurodegenerative diseases; microglial-mediated neuroinflammation, toxic protein build up, and vascular damage while restoring cognition. Our robust pipeline of drug candidates is designed for superior brain penetration and potency, representing a potential new generation of treatments for patients in urgent need. We are launching our $25M Series A financing this month to move our lead asset through a Phase 1a/1b clinical trial in Alzheimer’s disease.
Leapfrog Bio is a clinical-stage precision oncology company focused on the discovery and development of targeted therapeutics addressing loss-of-function (LOF) mutations, which drive roughly two-thirds of cancers (~10M U.S. patients). The company’s proprietary pharmacogenetics platform identifies novel synthetic lethality (SL) relationships between LOF mutations and clinical-stage small molecules, enabling efficient and de-risked drug development. Its lead program, LFB-190, is a differentiated BET inhibitor entering a Ph Ib/2a proof-of-concept study in early 2026 for the treatment of lung, bladder, head & neck, pancreatic, and other cancers with EP300 LOF mutations—an unaddressed and frequent genetic driver. There are currently no approved or clinical stage therapies for EP300-mutant cancers. LFB-190 represents a first-in-class opportunity with blockbuster potential. Backed by Two Bear Capital and led by an experienced oncology drug development team, Leapfrog is seeking $20M in Series A financing to fund its lead trial and advance additional pipeline programs.
Nalu Bio is transforming the future of health by unlocking the full potential of the endocannabinoid system (ECS), the body’s natural balancing network regulating pain, inflammation, immune function, and metabolism. The company’s AI-driven discovery platform designs and prioritizes novel, non-addictive compounds five times faster than traditional methods, accelerating the path from concept to clinic. Nalu Bio is addressing conditions linked to today’s biological mismatch—including chronic inflammation, immune dysregulation, and metabolic dysfunction—by developing precision-engineered alternatives to opioids, NSAIDs, and hormonal-based therapies. Lead programs target pain, inflammation, and endometriosis, with a broader pipeline extending into immune and metabolic diseases. Learn more at NaluBio.com and follow us on LinkedIn for the latest updates.
Nexture Bio is a novel materials company on a mission to redefine what and how materials are used in biotech by eliminating animal-derived inputs and replacing synthetic polymers with biopolymers that are more sustainable, scalable, and safe across biomedical, tissue engineering, cell therapy, nutraceuticals, food, and other applications. Nexture Bio’s offerings are built on the company’s unique IP portfolio, team experience, and skill set in materials science and materials for adherent cell culture. Today, products include animal-component-free (ACF) microcarriers and scaffolds, cell-attachment factors, and electrospun bioactive-loaded strips for supplement and drug delivery.
O2nix Bio is pioneering therapies that selectively target the oxidative stress-response mechanisms enabling metastatic cancer cells to survive and thrive. Our platform targets metastasis-enabling tRNAs and antioxidant translation. Based on foundational discoveries published in Nature and Nature Cancer and validated in pre-clinical models in vivo, O2nix Bio is advancing novel programs for melanoma, pancreatic, and lung cancers. By targeting metastatic cells’ unique vulnerabilities, O2nix Bio aims to deliver therapies where current treatments fail.
Object Pharma is developing OP01 for clinical use in treating depression, Major Depressive Disorder (MDD), entering a global market for anti-depressants valued at over $22b in 2024. OP01 is a novel therapeutic neurotoxin expected to treat depression alone or in combination with existing anti-depressants, given its local activity (non-systemic), minimal drug-drug interactions, and excellent safety profile. Object’s founder previously founded Bonti ($195 mil sale to Allergan) and the company is raising its Series A round to support OP01’s first clinical trial.
OncoPrecision has reengineered oncology drug discovery by integrating high-throughput patient-derived biology with AI/ML to develop antibody based therapies that overcome the translational gap and drive higher clinical success rates. Our platform has demonstrated clinical translation with >80% accuracy, unlocking an opportunity to bridge the gap of poor preclinical models that currently lead to a ~7% clinical success rate for oncology programs. We are a spin-out of Dr. Gastón Soria’s Synthetic Lethality Lab, which led multi-year oncology collaborations with GSK and uncovered numerous novel therapeutic targets. Our lead program—a first-in-class CD64-targeting ADC—has demonstrated compelling in vivo activity across monocytic leukemia and TAM-rich solid tumors, presenting a novel approach to overcoming monocyte-driven resistance with pipeline-in-a-product potential.
Orbit Genomics® is redefining precision medicine with OrbiSeq™, the first AI-powered platform that accurately analyzes short tandem repeats—dynamic, stress-responsive DNA sequences that reveal both inherited disease risk and risk acquired from living. Unlike traditional tests focused on static genetic mutations (SNPs), OrbiSeq delivers a personalized, actionable view of health and disease trajectory. Built on more than two decades of NIH-funded research, the OrbiSeq technology platform unlocks the genomic signals missed by standard sequencing, with validated applications in early disease diagnosis, companion diagnostics, therapeutic target discovery, and aging-related risk. With products in development across cancer, cardiovascular, neurological, and inflammatory diseases, Orbit Genomics is unlocking the missing piece of the genomics puzzle.
Pacylex is a clinical stage oncology company and the world leader in developing drugs inhibiting myristoylation, a protein modification essential to many cancer processes. Pacylex has 1) an oral drug in clinical development for acute myeloid leukemia (AML) with potential for a) other heme malignancies, b) synergy with immune checkpoint inhibitors (ICIs) like Keytruda ($29.5bn 2024) for solid tumors, and c) radiosensitization, and 2) an antibody drug conjugate (ADC) payload catalogue of 28 potent molecules with demonstrated activity and partner interest. Pacylex is the only company with an oral N-myristoyltransferase inhibitor (NMTi), zelenirstat, in clinical development, for which Orphan and Fast Track designations have been granted for AML. Published Phase 1 results in a study that included patients with 14 different types of cancer and an average of 4 prior lines of failed therapy, showed a better safety profile than traditional chemotherapy and statistically significant survival benefits.
QuantaPro focuses on proteins, proteoforms, metabolites and small molecules. Our patented technologies are integrated in a single common platform for discovery, validation, development of diagnostic and companion biomarker tests, patient-accessible testing kits and services, and validated biologic-drugs. Within-reach-approach to healthcare is of paramount importance, yet the largest segments of the world’s population do not have access to the most basic types of testing and medical care. One impediment is the blood-draw with syringe and needle; the other is the cost. When micro-volume blood collected by the patient on our Actionable Dried Blood Spot (ADBS) dries, most biological processes, such as enzymatic reactions come to a stop. Drying also inactivates microbes and viruses. Compared to liquid whole blood, dried blood on the ADBS is stable much longer, can be stored at room temperature, bio-safe, much less expensive and safe to globally transport by ordinary mail. Our ADBS testing kit is the solution to overcome this inequity. QuantaPro has all these transformative and disruptive capabilities -- under one roof!
Qureator is accelerating drug development and de-risking clinical trials with its human-relevant AI platform. Our proprietary "Human Disease Flywheel" uses patient-derived data to predict clinical efficacy with 95% accuracy, eliminating assets that would otherwise fail in Phase II. By ensuring our partners advance the right drugs, we make the path to market cheaper, faster, and more likely to succeed, directly addressing the key bottlenecks in modern pharma R&D.
Rakuten Medical is a clinical and commercial-stage biotech company advancing its investigational Alluminox™ platform, which is based on photoimmunotherapy. The company is developing the platform consisting of drug and device to treat cancers. Its lead asset, ASP-1929, an antibody-dye conjugate targeting EGFR, is currently in a global Phase 3 trial in combination with anti-PD-1 therapy. ASP-1929 has already received marketing approval in Japan since 2021 for unresectable, locally advanced, or recurrent head and neck cancer. As of today, the company has completed over 900 commercial treatments in Japan.
ReEngage is developing novel small molecule inhibitors to a metabolic target, acetyl co-A synthetase (ACSS2), as a treatment for solid tumors. We have shown ACSS2 inhibitor MTB-9655 to be safe and tolerable in a phase 1 clinical study, and for a number of patients it slowed disease progression. We have elucidated MTB-9655 mechanism of action - downregulating expression of DNA damage repair genes, which contribute to chemo resistance. Further, MTB-9655 plus chemo in colorectal cancer (CRC) patient-derived xenograft models was shown to extend median survival by 50% over chemo-alone.
Resurge Therapeutics is a clinical-stage urology company developing IntraProstatic Drug Elution (IPDE) therapy, a one-time, in-office intraprostatic drug treatment. IPDE targets benign prostatic hyperplasia (BPH), a large and underserved market. In 31 patients treated to date, our fast, pain-free therapy has demonstrated durable efficacy out to 12 months. Following a successful $5M seed round, we are now raising $20M in a Series A to advance our lead program into a randomized controlled U.S. clinical trial.
Sanegene Bio, a clinical stage global biotech company is advancing the next generation of RNAi therapeutics through its innovative LEAD™ technology for best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases.
Sarcomatrix Therapeutics is developing first-in-class oral small molecules to treat muscle-wasting diseases, including Duchenne Muscular Dystrophy and sarcopenia. Our lead candidate, S-969, modulates muscle-repair pathways to increase α7β1 integrin activity and drive functional regeneration, providing a scalable, reversible, and cost-effective alternative to gene therapy. Backed by $8M in non-dilutive NIH funding, Orphan Drug designations in the U.S. and EU, and 75+ issued patents, we are completing IND-enabling work with first-in-human studies targeted for early 2026. Our lean, partnership-driven model prioritizes capital efficiency and rapid translation of science into patient benefit.
SciTech Development Inc. is a clinical-stage oncology company dedicated to developing innovative, effective, and accessible cancer therapeutics. Its lead candidate, ST-001 nanoFenretinide™, is a patented drug currently in clinical trials for T-cell lymphoma (a subtype of non-Hodgkin lymphoma). Interim data has shown a 100% disease control rate at the two highest dose levels tested to date, with patients achieving partial and stable disease responses. ST-001 has demonstrated a favorable safety profile, successful delivery to targeted tissue, and improved bioavailability.
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues.
Sustained Therapeutics is a clinical-stage company developing a patented sustained-release drug delivery platform for localized delivery of approved drugs serving large unmet medical needs with significant market potential. Its lead product (ST-01) is a non-opioid medication for the treatment of chronic, neuropathic and post-surgical pain. A phase I study has been successfully completed and two phase II studies are underway, one in acute post-operative pain and one in chronic pain. A successful interim review of data from the Phase II chronic pain trial has been carried out, with promising results. This review covered data at the trial’s 80% completion point (50 of 63 patients treated). The study is now fully enrolled and completion is anticipated in Q4 2025. Commencement of a Phase III trial in chronic pain is planned for 2026.
Synfini is transforming small molecule drug discovery by uniting the virtual and physical through combination of AI-driven molecular design with advanced automated synthesis technologies. Our platform empowers drug hunters to rapidly explore chemical space, generate novel compounds, and validate them with unprecedented speed and efficiency. By combining computational intelligence with physical automation, Synfini reduces discovery timelines and cost, and increases the probability of success, enabling new medicines to reach patients faster.
Synlico was founded to reveal genuine cause-and-effect mechanisms in human biology - moving beyond correlations. Our platform offers an intrinsically causal AI approach: we decode causal relationships and biological heterogeneity directly from primary patient data, by combining generative modeling with state-of-the-art causal structure discovery & inference to deliver a truly differentiated solution.
TaiMed Biologics, Inc. is a Taiwan-based biopharmaceutical company focused on the research, development and manufacturing of innovative biologics. The company developed and with strategic partners, markets Trogarzo® (ibalizumab-uiyk), the first FDA-approved monoclonal antibody for multidrug-resistant HIV, available in the U.S., EU, and other global markets. Leveraging proven expertise in biologics R&D, regulatory approval, and GMP manufacturing, TaiMed is advancing a pipeline of next-generation HIV antibodies and antibody-drug conjugates. The company is also pursuing global partnerships and CDMO opportunities to expand patient access and drive long-term growth.
ThinkBio.Ai® is a next-generation Digital Biology and AI platforms and solutions company dedicated to transforming the BioPharma and Clinical Healthcare industries by delivering impactful solutions that drive efficiencies in both drug research and clinical practice. By leveraging deep domain expertise in specialized areas such as oncology, immunology, cardiology, and neurology, and utilizing proprietary platforms that incorporate knowledge graphs, digital twins, foundation models, and AI/ML pipelines, we develop and license advanced platforms and solutions that accelerate drug discovery and optimize clinical pathways. The secure federated architecture of our platforms empowers clients to seamlessly integrate their data with knowledge insights from ThinkBio.Ai® and third parties, unlocking powerful, AI-driven insights in an explainable environment to drive therapeutic and research breakthroughs.
Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the work at Zena focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other CNS depressants such as opioids and alcohol. Our novel compound has shown, via preliminary studies, favorable pharmacokinetics, robust anxiolytic activity (in rats,) and favorable safety characteristics. The commercialization of this compound will not only help individuals with general anxiety and panic disorders but also those suffering from withdrawal induced-anxiety (namely from opioid use disorder and alcohol use disorder) who otherwise would not be candidates for other fast acting anxiolytics, due to the risk of overdose. Our overall mission is to lead way in raising safety standards for commonly misused CNS medications to ensure that the consequence of medication misuse is never death.